Cogent Biosciences Inc. (COGT) carries a Roarable Rating of C (Hold) with 63/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
Cogent Biosciences Inc. (COGT) slipped -0.84% to $31.96 as options desks priced 54% call premium vs. 46% put protection around the $31 max-pain magnet. Solid 41% profit margin (-35% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.
WALTHAM, Mass. and BOULDER, Colo., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today anno
Cogent Biosciences (NASDAQ:COGT) has outperformed the market over the past 5 years by 19.53% on an annualized basis producing an average annual return of 30.65%. Currently, Cogent Biosciences has a market capitalization
Three Regulatory Reviews, No Established Earnings Base Cogent Biosciences, Inc. (NASDAQ:COGT) has moved from proving bezuclastinib’s clinical activity to seeking regulatory approvals across distinct diseases. Its immedia
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +22.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on COGT today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for COGT. Explore sector supply chains on /butterfly.
Why COGT Stock slipped -0.84% Today — RQD Quant Desk Flash. Solid 41% profit margin (-35% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.